Announcement
On June 30, 2026, Shantha Biologics, a Hyderabad‑based pharmaceutical manufacturing company, issued a press release stating that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill‑finish manufacturing services in India. The agreement is described as an outsourcing collaboration and will be executed under a mutually agreed contractual framework that adheres to applicable quality, compliance and regulatory requirements.
Financial Terms
The company explicitly disclosed that no financial terms or further details of the agreement are being disclosed.
Executive Comment
Dr. Vishy Chebrol, Director of Shantha Biologics, said, "We are pleased to enter into this collaboration, which reflects the confidence placed in Shantha Biologics' capabilities and our commitment to reliable, high‑quality cartridge fill‑finish services. We look forward to supporting this partnership through strong operational execution and a continued focus on quality and compliance."
About Shantha Biologics
Shantha Biologics is a pharmaceutical manufacturing firm headquartered in Hyderabad, India, with capabilities that span vaccines, biologics, and specialized sterile manufacturing, including purpose‑built sterile fill‑finish capacity such as cartridge filling. The company partners with global pharmaceutical and biotechnology companies to deliver development and aseptic manufacturing that meets international quality and compliance standards.
Media Contacts
- Dr MRK Raju, +91 996 358 1033, mrkraju@shanthabiologics.com
- Sashi Pochimcharla, +91 994 905 4060, sashikanthp@shanthabiologics.com